L
Leon nanodrugs
Leon-nanodrugs is a nanotechnology-based drug development company focused on novel reformulations and reinventions of established drugs
About Leon nanodrugs
Leon-nanodrugs GmbH is a Munich-based company specializing in nanotechnology for the pharmaceutical industry. The company revitalizes forgotten formulations, breathes new life into generics, and expedites active pharmaceutical ingredients (APIs) to deliver enhanced bioavailability, increased solubility, and improved stability. Leon-nanodrugs serves pharmaceutical companies looking to improve the efficacy and stability of their drug formulations. Operating in the highly specialized nanotechnology market, the company leverages its proprietary technology to create value for its partners and address unmet medical needs. The business model revolves around providing novel, ready-to-use, validated nano solutions that enhance the performance of pharmaceutical products. Revenue is generated through partnerships, licensing agreements, and service contracts with pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 87.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Tech for Biotech and Pharma, Techbio, Woman Founder, DT and LS
- Technology
- Hardware, Deep Tech, Nanotech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Feb 2026 | $0 | — | Undisclosed | ↗ |
| SERIES DEquity / VC | Aug 2024 | $0 | — | Signet Healthcare Partners · CD-Venture · TVM Capital Life Science | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Leon nanodrugs is 1.3K monthly website visits, up 306.3% over the last three months. Leon nanodrugs's team grew 53.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Leon nanodrugs in the Munich ecosystem
The Leon nanodrugs office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
TVM Capital Life Science
Signet Healthcare Partners- CDCD-Venture
- LPLifeCare Partners
Evotec- AHAlbany Private Equity Holdings
- LPLOF Leon Partnership
- ECEckenstein-Geigy-Stiftung
Other known investors3 additional known investors
Bavarian SME Equity Investment Company
BayBG Venture Capital
LBBW Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Leon nanodrugs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Leon nanodrugs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








